FDA Approves Neladalkib for Previously Treated ALK-Positive Lung Cancer
The FDA has granted accelerated approval to neladalkib for advanced ALK-positive non-small cell lung cancer patients who have undergone prior treatments.
❤️Conditions & CarePhoto: medpagetoday.com
Key points
- FDA granted accelerated approval to neladalkib for advanced ALK-positive NSCLC.
- Approval is based on the single-arm ALKOVE-1 trial involving 222 participants.
- Common side effects include elevated liver enzymes, fatigue, and musculoskeletal pain.
New Targeted Option for Advanced NSCLC
Federal regulators have granted accelerated approval to the third-generation ALK inhibitor neladalkib, marketed as Nelkarmi, providing a new option for patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The indication covers individuals with unresectable locally advanced or metastatic disease who have previously received alectinib or at least two prior ALK tyrosine kinase inhibitors alongside platinum-based chemotherapy.
Approval was supported by findings from the phase I/II single-arm ALKOVE-1 clinical trial involving 222 participants. Among 67 patients previously treated solely with alectinib in the metastatic setting, the therapy prompted responses in 49%, with 76% maintaining that response for at least six months. For a broader group of 155 heavily pretreated patients who received two or more prior ALK inhibitors and chemotherapy, the response rate reached 32%. Investigators noted common adverse events included elevated liver enzymes, musculoskeletal pain, and fatigue, accompanied by prescribing warnings for hepatotoxicity, renal toxicity, and other risks.
What to know: While clinical trial data suggest promising response durations and efficacy even in some patients with brain metastases, the findings stem from a single-arm study rather than a randomized trial. Patients should consult their oncologists regarding personalized treatment sequences and potential side effects.
Source medpagetoday.com — medpagetoday.com/hematologyoncology/lungcancer/123937 ↗
Read next
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.
🧠Mind & Mental HealthThe Role of Daily Mobility Training in Managing Sedentary Tension
A two-week personal trial suggests that incorporating short, daily mobility exercises may help alleviate stiffness associated with sedentary desk work. Experts note that …
🧠Mind & Mental HealthNew Theoretical Framework Explores Memory Formation and Dementia
Researchers have proposed a new model suggesting the brain's limbic system functions similarly to generative AI, potentially offering a new way to understand and classify…